Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of ...

Learn more about whether Amarin Corporation plc or Catalyst Pharmaceuticals, Inc. is a better investment based on AAII's A+ ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Canada, Kye Pharmaceuticals, has announced that Health Canada has accepted ...

is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key treatment for decades, they are not currently approved for DMD ...

AGAMREE, which is already approved and available in the United States, could become the first authorized DMD treatment in Canada if approved. The drug, a corticosteroid designed to maintain ...

AGAMREE, which is already approved and available in the United States, could become the first authorized DMD treatment in Canada if approved. The drug, a corticosteroid designed to maintain efficacy ...

MISSISSAUGA, ON - Kye Pharmaceuticals Inc. has submitted a New Drug Submission (NDS) to Health Canada for AGAMREE® (vamorolone), a potential treatment for Duchenne muscular dystrophy (DMD), the ...

MISSISSAUGA, ON - Kye Pharmaceuticals Inc. has submitted a New Drug Submission (NDS) to Health Canada for AGAMREE® (vamorolone), a potential treatment for Duchenne muscular dystrophy (DMD), the ...